The adverse reaction to menin inhibitors is not limited to typical differentiation syndrome (DS) pulmonary symptoms. It presents as a broad 'menin syndrome' with diverse manifestations like bone pain, rashes, and swollen lymph nodes, requiring a new diagnostic framework for clinicians.

The differentiation syndrome (DS) from menin inhibitors is often more severe and rapid than seen with other AML drugs. It can escalate into a "crisis" with DIC and heart failure, requiring an immediate drug pause, steroids, and potentially cytoreduction.

Menin inhibitors achieve high rates of MRD-negative remissions. However, the median duration is very short (4-6 months), suggesting current MRD assays may not adequately capture residual disease and that "MRD negativity" is not a reliable predictor of long-term benefit for this drug class.

Differentiation syndrome with menin inhibitors is more frequent and intense than with IDH inhibitors, meaning clinicians cannot be complacent. It requires an emergency-level response: immediate hospital admission, steroids, holding the drug, and a low threshold to escalate treatment with cytarabine if needed.

Similar to FLT3 inhibitors like midostaurin, which failed in the relapsed setting but succeeded upfront, menin inhibitors are expected to show dramatically better efficacy when combined with standard induction or HMA/Venetoclax in newly diagnosed patients.

The differentiation syndrome with menin inhibitors can be far more severe than with other agents, manifesting as a life-threatening, HLH-like state with massive inflammatory marker elevation (e.g., ferritin >300,000) that may be unresponsive to high-dose steroids.

Combining menin inhibitors with intensive chemotherapy can decrease the risk of differentiation syndrome, a severe side effect. The chemotherapy debulks the tumor, reducing the number of malignant cells available to cause this inflammatory reaction when they differentiate, improving tolerability.

Unlike typical targeted therapies that block a mutated receptor, menin inhibitors work by disrupting a master transcription complex. This forces leukemic cells to mature (differentiate) into terminal forms like neutrophils, after which they naturally die off.

When menin inhibitors are combined with a chemotherapy backbone like induction or Aza/Ven for newly diagnosed AML, the risk of differentiation syndrome (DS) is significantly lower than when they are used as monotherapy in the relapsed setting.